Growth Metrics

Neurocrine Biosciences (NBIX) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $153.7 million.

  • Neurocrine Biosciences' Income towards Parent Company rose 4907.86% to $153.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $478.6 million, marking a year-over-year increase of 4022.85%. This contributed to the annual value of $478.6 million for FY2025, which is 4022.85% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Income towards Parent Company of $153.7 million as of Q4 2025, which was up 4907.86% from $209.5 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Income towards Parent Company ranged from a high of $209.5 million in Q3 2025 and a low of -$76.6 million during Q1 2023
  • Over the past 4 years, Neurocrine Biosciences' median Income towards Parent Company value was $83.1 million (recorded in 2023), while the average stood at $77.8 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Income towards Parent Company skyrocketed by 15665.8% in 2024, and later plummeted by 8179.72% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Income towards Parent Company stood at $22.5 million in 2021, then soared by 556.44% to $147.7 million in 2023, then crashed by 30.2% to $103.1 million in 2024, then surged by 49.08% to $153.7 million in 2025.
  • Its last three reported values are $153.7 million in Q4 2025, $209.5 million for Q3 2025, and $107.5 million during Q2 2025.